Abstract:
The gastrointestinal (GI) mucosal barrier is often exposed to inflammatory and erosive insults, resulting in gastric lesions. Glycosaminoglycans (GAGs), such as hyaluronic acid (HA), chondroitin sulfate (CS), and N-acetylglucosamine (NAG) have shown potential beneficial effects as GI protectants. This study aimed to evaluate the gastroprotective effects of oral GAGs in rats with indomethacin-induced GI lesions. Forty-five Sprague-Dawley rats (8-9 weeks-old, 228 ± 7 g) were included in the study, divided into five study groups, and given, administered orally, either sucralfate (positive control group; PC), NAG (G group), sodium alginate plus HA and CS (AHC group), sodium alginate plus HA, CS, and NAG (AHCG group), or no treatment (negative control group; NC). Animals were administered 12.5 mg/kg indomethacin orally 15 min after receiving the assigned treatment. After 4 h, stomach samples were obtained and used to perform a macroscopic evaluation of gastric lesions and to allow histological assessment of the gastric wall (via H/E staining) and mucous (via PAS staining). The AHCG group showed significant gastroprotective improvements compared to the NC group, and a similar efficacy to the PC group. This combination of sodium alginate with GAGs might, therefore, become a safe and effective alternative to prescription drugs for gastric lesions, such as sucralfate, and have potential usefulness in companion animals.
摘要:
胃肠道(GI)粘膜屏障经常暴露于炎症和糜烂的损伤,导致胃部病变.糖胺聚糖(GAG),如透明质酸(HA),硫酸软骨素(CS),和N-乙酰葡糖胺(NAG)已显示出作为GI保护剂的潜在有益效果。这项研究旨在评估口服GAG对吲哚美辛诱导的胃肠道病变大鼠的胃保护作用。45只Sprague-Dawley大鼠(8-9周大,228±7克)纳入研究,分为五个研究组,并给出了,口服给药,硫糖铝(阳性对照组;PC),NAG(G组),海藻酸钠加HA和CS(AHC组),海藻酸钠加HA,CS,和NAG(AHCG组),或不治疗(阴性对照组;NC)。动物在接受指定的治疗后15分钟口服施用12.5mg/kg吲哚美辛。4小时后,获得胃样本,并用于对胃部病变进行宏观评估,以及对胃壁(通过H/E染色)和粘液(通过PAS染色)进行组织学评估.与NC组相比,AHCG组表现出明显的胃保护性改善,疗效与PC组相似。海藻酸钠与GAG的这种组合可能,因此,成为胃部病变处方药的安全有效替代品,比如硫糖铝,并对伴侣动物有潜在的用处。